CRISPR Therapeutics registers Phase 1/2 trial of CTX112 in neurologic autoimmune disease

CRISPR Therapeutics registered one new trial this week.

• The Phase 1/2 trial (NCT07804004, sponsor study ID CRSP-AID-502) is listed as not yet recruiting, with an estimated start date of 2026-11-01 and estimated primary completion of 2029-12-30.¹ The trial may enroll up to 220 participants.¹ It will evaluate CTX112, also called Zugocabtagene geleucel or zugo-cel, a CD19-directed allogeneic CAR-T cell therapy made using CRISPR-Cas9 gene editing, in adults with Progressive Multiple Sclerosis, relapsing Neuromyelitis Optica Spectrum Disorder, relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, refractory Autoimmune Encephalitis, and refractory Stiff-Person Syndrome.¹ The primary outcome is safety of CTX112 through 28 days post-infusion, including incidence of dose-limiting toxicities.¹